Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib Plus CIK in Advanced Gastric Cancer
NCT02485015Phase 2Active, not recruiting
- Sponsor
- Changzhou First People's Hospital
- Start
- Jun 2015
- Primary completion
- Jun 2030
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
01
Overview
A Phase 2 trial of unmodified CIK in gastric cancer (GC), sponsored by Changzhou First People's Hospital. Started Jun 2015; status: active, not recruiting.
02
Drugs
unmodified CIK
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT02485015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02485015.